It is necessary to adopt specific provisions for immunological medicinal products, homeopathic medicinal products, radiopharmaceuticals, and medicinal products based on human blood or human plasma.
Recital 17, Directive (EU) 2001/83
Judgment of the Court (Eighth Chamber) of 23 April 2020. Deutsche Homöopathie-Union (DHU) Arzneimittel GmbH & Co. KG v Bundesrepublik DeutscDecision
Recitals 2, 5, 17, 21, 23, 25 and 40 of Directive 2001/83 are worded as follows: The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health. … Such hindrances …
23 Apr 2020 · 62019CJ0101
Opinion of Advocate General Jääskinen delivered on 7 November 2013. Octapharma France SAS v Agence nationale de sécurité du médicament et deDecision
Directive 2001/83 entered into force in December 2001. [See Article 129 of Directive 2001/83.] Even prior to its amendments by Directive 2004/27, it contained specific provisions appertaining to blood and plasma. Recital 17 states that it …
7 Nov 2013 · 62012CC0512